APOE and dementia: Given the central role of CETP in lipid metabolism and the fact that CETP inhibition influences HDL composition of Apo-E [28] as well as brain cholesterol concentration [29], the CETP inhibitor obicetrapib is now being considered for treatment of dementia which is tested in a large phase II clinical trial (BROADWAY).